Richard Milner, Ph.D. publishes on his finding that, Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation

Dr. Milner’s recent study aimed to clarify the therapeutic potential of activated protein C (APC) in the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). His study showed that APC suppressed clinical progression of EAE and mechanistic studies revealed that this was due, in part, by enhancing vascular integrity and suppressing microglial activation. Together, these studies demonstrate strong therapeutic potential for APC in the treatment of inflammatory demyelinating diseases such as MS.